TABLE 4.
Active Material Coated | Coating Method | Total Amount Coated (Total Microneedle Shafts in the Patch That Are Coated)a/b |
---|---|---|
Viruses and bacteria | ||
Bacillus Calmette-Guérin vaccine | Dip | 0.83 μg (5 microneedles)a (Hiraishi et al., 2011) |
Francisella novicida | Immersion | 2.5 × 106 CFU/ml (77 microneedles)b (Chandler et al., 2018) |
Human papillomavirus: Gardasil | Drop–gas jet | 300ng–0.43 ng HPV vaccine (3364 microneedles)b (Corbett et al., 2010) |
Inactivated chikungunya virus | Drop–gas jet | 0.38 μg (3364 microneedles)b (Prow et al., 2010) |
Inactivated polio virus | Drop–gas jet | 1 D-antigen units (10,000 microneedles)b (Muller et al., 2016) |
Inactivated split influenza virus | Dip | 3 μg (5 microneedles)a (Koutsonanos et al., 2012) |
Inactivated split influenza virus | Dip | 30–45 μg (320 microneedles)a (Kommareddy et al., 2013) |
Inactivated split influenza virus | Drop–gas jet | 37 ng (3364 microneedles)b (McNeilly et al., 2014) |
Inactivated split influenza virus | Drop–gas jet | 15 μg hemagglutinin (10,000 microneedles)b (Fernando et al., 2018) |
Inactivated whole influenza virus | Dip | 0.4 μg (5 microneedles)a (Quan et al., 2009) |
Inactivated whole influenza virus | Dip | 3 or 10 μg (5 microneedles)a (Koutsonanos et al., 2009) |
Inactivated rotavirus vaccine | Dip | 5 or 0.5 μg (5 microneedles)a (Moon et al., 2013) |
Live measles vaccine virus | Dip | 200 or 1000 TCID50 (5 microneedles)a (Edens et al., 2013) |
Pneumococcal-conjugate vaccine | Drop–gas jet | 1 μg (21,400 microneedles)b (Pearson et al., 2015) |
Trivalent inactivated whole influenza viruses | Dip | 6 μg ((5 microneedles)a (Kim et al., 2016b) |
Virus-like particles (VLPs) | ||
Influenza VLPs | Dip | 0.4 μg (5 microneedles)a (Song et al., 2010) |
Influenza VLPs | Dip | 10 μg (5 microneedles)a (Pearton et al., 2013) |
Oligonucleotides | ||
DNA vaccine (hepatitis C virus, nonstructural 3/4 A protein) | Dip | 1.6 μg (5 microneedles)a (Gill et al., 2010) |
DNA vaccine (herpes simplex virus type 2 US6) | Drop–gas jet | 400–4 ng (3364 microneedles)b (Kask et al., 2010) |
DNA vaccine (influenza virus hemagglutinin) | Dip | 3.6 μg DNA (5 microneedles)a (Kim et al., 2012) |
DNA vaccine (influenza virus nucleoprotein) | Drop–gas jet | 10 μg (3364 microneedles)b (Fernando et al., 2016) |
DNA vaccine (Leishmania) | Dip | 20 μg DNA (10 microneedles)a (Moreno et al., 2017) |
Oligonucleotide | Dip | 0.136 nmol (5 microneedles)a (Luo et al., 2013) |
siRNA | Dip | 40 μg (10 microneedles)a (Chong et al., 2013) |
Peptides and proteins | ||
Bevacizumab (antibody) | Dip | 1.1 μg (5 microneedles)a (Kim et al., 2014) |
Bovine serum albumin (protein) | Dip | 30 μg (64 microneedles)a (Caudill et al., 2018) |
Bovine serum albumin (protein) | Dip | 20–100 μg (50 microneedles)a (Andrianov et al., 2009) |
Der p1 (house dust mite allergen protein) | Dip | 25 ± 25 μg CpG (57 microneedles)a (Shakya et al., 2018) |
Desmopressin (peptide) | Dip | 82 μg (642 microneedles)a (Cormier et al., 2004) |
Diphtheria toxoid (protein) | Layer-by-layer | 0.05–0.6 μg (576 microneedles)b (Schipper et al., 2017) |
Ebola virus glycoprotein | Dip | 0.63 μg (5 microneedles)a (Liu et al., 2018) |
Erythropoietin (protein) | Dip | 200 μg (1950 microneedles)a (Peters et al., 2012) |
Exendin-4 (peptide) | Dip | 0.5–4 μg (140 microneedles)a (Liu et al., 2016) |
M2e-flagellin (fusion protein) | Dip | 1.4 μg (5 microneedles)a (Wang et al., 2014) |
Ovalbumin (protein) | Dip | 25 ± 25 μg CpG (57 microneedles)a (Shakya et al., 2017) |
Ovalbumin (protein) | Drop–gas jet | 5 μg OVA (3364 microneedles)b (Ng et al., 2012) |
Parathyroid hormone peptide | Dip | 20, 30, 40 μg (1300 microneedles)a (Daddona et al., 2011) |
Peptides and CpG (oligonucleotide) | Layer-by-layer | 5 to 6 μg (77 microneedles)b (Zeng et al., 2017) |
Recombinant human growth hormone (protein) | Dip | 500 μg (1740 microneedles)a (Ameri et al., 2014) |
Salmon calcitonin (cyclic polypeptide) | Dip | 1.5 μg (5 microneedles)a (Tas et al., 2012) |
Small molecules | ||
5-Aminolevulinic acid | Dip | 206–680 μg (57 microneedles)a (Jain et al., 2016) |
Alendronate | Dip | 15 μg (190 microneedles)a (Katsumi et al., 2017) |
Bleomycin | Dip | 62–518 μg (100 microneedles)a (Lee et al., 2017a) |
Calcein | Dip | 0.13–21 μg (144 microneedles)a (Chen et al., 2015) |
Curcumin, 5-fluorouracil, sodium fluorescein | Inkjet | 24–118 μg (50 microneedles)a (Uddin et al., 2015) |
Doxorubicin encapsulated in particles | Dip | 0.6 μg (5 microneedles)a (Ma et al., 2015) |
Lidocaine | Dip | 45–94 μg (316 microneedles)a (Zhang et al., 2012b) |
Lidocaine | Dip | 290 μg (256 microneedles)a (Baek et al., 2017) |
Lidocaine | Dip (molten drug) | 15 μg (5 microneedles)a (Ma and Gill, 2014) |
Paclitaxel | Dip | 1 μg (9 microneedles)a (Lee et al., 2014) |
Sulforhodamine | Dip | 132–835 ng (25 microneedles)a (Chen et al., 2017) |
Sulforhodamine | Dip | 15 μg (57 microneedles)a (Serpe et al., 2016) |
Zolmitriptan | Dip | 1.9 mg (1987 microneedles)a (Spierings et al., 2018) |
3.8 mg (microneedle number unclear)a (Kellerman et al., 2017) |
Amount coated on microneedle shafts.
Amount delivered into skin (for coating methods that generate coatings on microneedle shaft and base of patch).